Abstract
To advance understanding of the heterogeneity in the course of ADHD, joint symptom trajectories of inattention and hyperactivity-impulsivity from childhood to young adulthood were modelled and associated with genetic, demographic, and clinical characteristics. Data were obtained from the NeuroIMAGE cohort which includes 485 individuals with ADHD, their 665 siblings, and 399 typically developing children. Trajectories were based on scores of the Conners Parent Rating Scale Revised and estimated over seven homogeneous age bins (from 5 to 28 years) using parallel process latent class growth analysis on data collected across 2–4 time points. Multilevel multinomial logistic regression was used to identify characteristics that differentiated between the derived classes. A seven-class solution revealed “severe combined stable” (4.8%), “severe combined decreasing” (13%), “severe inattentive stable” (4.8%), “moderate combined increasing” (7.5%), “moderate combined decreasing” (12.7%), “stable mild” (12.9%), and “stable low” (44.3%) classes. Polygenic risk for depression, ADHD diagnosis, ADHD medication use, IQ, comorbid symptom levels (foremost oppositional behaviour), and functional impairment levels differentiated classes with similar ADHD symptom levels in childhood but a diverging course thereafter. The course of ADHD is highly heterogeneous, with stable, decreasing, and increasing trajectories. Overall, severe symptom levels in childhood are associated with elevated-to-severe symptom levels in adolescence and young adulthood, despite substantial symptom reductions. Beyond symptom severity in childhood, genetic, demographic, and clinical characteristics distinguish the heterogeneous course.
| Original language | English |
|---|---|
| Pages (from-to) | 1243-1253 |
| Number of pages | 11 |
| Journal | European Child and Adolescent Psychiatry |
| Volume | 31 |
| Issue number | 8 |
| Early online date | 3 Apr 2021 |
| DOIs | |
| Publication status | Published - Aug 2022 |
Bibliographical note
Funding Information:This study made use of the longitudinal NeuroIMAGE study. The NeuroIMAGE cohort consists of the Dutch part of the International Multisite ADHD Genetics (IMAGE) project, an intermediate follow-up study, and the two follow-up studies as part of the NeuroIMAGE project. Funding support for the IMAGE project was provided by National Institutes of Health (NIH) Grants R01MH62873 and R01MH081803 (to Stephen V. Faraone). The intermediate follow-up study was supported by an unrestricted Grant from Shire Pharmaceuticals (to Stephen V. Faraone) and by a Grant from The Netherlands Organization for Health Research and Development (ZonMw) (60-60600-97-193 to Jan K. Buitelaar). The follow-up and extension studies of the NeuroIMAGE project were supported by an Netherlands Organization for Scientific Research (NWO) Large Investment Grant 1750102007010 and NWO Brain & Cognition an Integrative Approach Grant (433-09-242) (to Jan K. Buitelaar), and Grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, VU University Amsterdam, and by the ECNP Network ADHD across the Lifespan. The research leading to these results also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under Grant agreement numbers 278948 (TACTICS) and 602805 (Aggressotype) and from the European Community’s Horizon 2020 Programme under Grant agreement number 667302 (CoCA). Barbara Franke is supported by a personal Vici Grant from the Netherlands Organization for Scientific Research (NWO; Grant 016-130-669). Additional support is received from the Dutch National Science Agenda for the NWANeurolabNL project (Grant 400 17 602). Part of this work was carried out on the Dutch national e-infrastructure with the support of SURF Foundation. We thank all PhD students for their contribution to the data acquisition and are grateful to all participating families.
Publisher Copyright:
© 2021, The Author(s).
Funding
This study made use of the longitudinal NeuroIMAGE study. The NeuroIMAGE cohort consists of the Dutch part of the International Multisite ADHD Genetics (IMAGE) project, an intermediate follow-up study, and the two follow-up studies as part of the NeuroIMAGE project. Funding support for the IMAGE project was provided by National Institutes of Health (NIH) Grants R01MH62873 and R01MH081803 (to Stephen V. Faraone). The intermediate follow-up study was supported by an unrestricted Grant from Shire Pharmaceuticals (to Stephen V. Faraone) and by a Grant from The Netherlands Organization for Health Research and Development (ZonMw) (60-60600-97-193 to Jan K. Buitelaar). The follow-up and extension studies of the NeuroIMAGE project were supported by an Netherlands Organization for Scientific Research (NWO) Large Investment Grant 1750102007010 and NWO Brain & Cognition an Integrative Approach Grant (433-09-242) (to Jan K. Buitelaar), and Grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, VU University Amsterdam, and by the ECNP Network ADHD across the Lifespan. The research leading to these results also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under Grant agreement numbers 278948 (TACTICS) and 602805 (Aggressotype) and from the European Community’s Horizon 2020 Programme under Grant agreement number 667302 (CoCA). Barbara Franke is supported by a personal Vici Grant from the Netherlands Organization for Scientific Research (NWO; Grant 016-130-669). Additional support is received from the Dutch National Science Agenda for the NWANeurolabNL project (Grant 400 17 602). Part of this work was carried out on the Dutch national e-infrastructure with the support of SURF Foundation. We thank all PhD students for their contribution to the data acquisition and are grateful to all participating families.
| Funders | Funder number |
|---|---|
| Surfrider Foundation | |
| Shire | |
| European Commission | |
| Radboud Universitair Medisch Centrum | |
| Vrije Universiteit Amsterdam | |
| European College of Neuropsychopharmacology | |
| European Community’s Horizon 2020 Programme | |
| Chiropractic and Osteopathic College of Australasia | 016-130-669 |
| Dutch National Science Agenda | 400 17 602 |
| Seventh Framework Programme | 602805, 278948 |
| NWO | 1750102007010, 433-09-242 |
| Horizon 2020 Framework Programme | 667302 |
| National Institutes of Health | R01MH62873, R01MH081803 |
| ZonMw | 60-60600-97-193 |
Keywords
- ADHD
- Heterogeneity
- Late-onset
- Polygenic risk scores
- Trajectories